We proposed to identify the efficacy of an epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor (TKI) using whole brain radiotherapy (WBRT)/stereotactic radiosurgery …

Lung cancer remains a leading cause of mortality with 1.69 million deaths worldwide.
Activating mutations in epidermal growth factor receptor (EGFR), predominantly exon 19 …

Osimertinib, as a third‐generation epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor (TKI), showed more potent efficacy against brain metastasis (BM) in untreated …

Background NSCLC patients with EGFR mutation were at a higher incidence of developing
brain metastasis (BM). Patients with BM are associated with high mortality. Reducing BM …

Background Molecular and genetic alterations of non-small-cell lung cancer (NSCLC) now
play a vital role in patient care of this neoplasm. The authors focused on the impact of …

Identification of epidermal growth factor receptor (EGFR) as a molecular target has radically
changed the treatment of metastatic non-small cell lung cancer (NSCLC) from standard …

Opinion statement Management of non-small cell lung cancer (NSCLC) with brain
metastasis (BrM) has been revolutionized by identification of molecular subsets that have …

Background Osimertinib was approved as a standard therapy for EGFR-mutant lung cancer
with brain metastasis. It has been demonstrated that TP53 mutations was responsible for …

Background EGFR-mutant non-small cell lung cancer (NSCLC) is prone to leptomeningeal
metastasis (LM) after Tyrosine kinase inhibitors (TKIs) treatment. Our previous study …

Background The standard therapy for brain metastasis (BM) in non-small cell lung cancer
(NSCLC) is radiation therapy (RT), although it is associated with complications such as …